No Detail Found!

Response and Tolerability of Sofosbuvir Plus Velpatasvir in Patients With Hepatitis C Related Liver Cirrhosis

Author(s)
Muhammad Irfan Department of Medicine & Gastroenterology, SIMS, Lahore, Pakistan
Imran Anwar Khan Department of Medicine & Gastroenterology, Airdale General Hospital, Keighley, UK
Naveed Aslam Department of Gastroenterology, Gujranwala Medical College,GujranwalaPakistan
Ahsen Naqvi Department of Medicine, RLM, Lahore, Pakistan
Muhammad Haseeb Nawaz Department of Medicine & Gastroenterology, SIMS, Lahore, Pakistan
Muhammad Arif Nadeem Department of Medicine & Gastroenterology, SIMS, Lahore, Pakistan
Abstract
Objective: To determine the response and tolerability of Sofosbuvir plus Velpatasvir in patients with hepatitis C related liver cirrhosis in the studied Pakistani population. Our study also compared cirrhotic patients with non-cirrhotic ones in terms of treatment effectiveness as well as safety. Material and Methods: This was a prospective observational study11 performed at Department of Medicine, Hepatology and Gastroen-terology, SIMS/Services hospital, Lahore, from January 2022 to December 2022. The enrolled 100 patients were grouped into Group A (non-cirrhotic hepatitis C patients) and Group B (compensated cirrhotic hepatitis C patients). Sofosbuvir plus Velpatasvir was given to group A patients for 12 weeks & to group B patients for 24 weeks. Laboratory findings, response and adverse effects were recorded four weekly. The data was analysed using SPSS version 27. Comparisons were done between two studied patient's groups in terms of effectiveness and tolerability of the treatment. The p-values were significant if <0.05. Results: ETR and SVR-12 were 98.1% and 94.3% in group A and 95.7% and 93.6% in group B. SVR-12 was comparable in two groups (p= 0.602). No adverse event leading to treatment withdrawal was reported in either group. However, mild worsening of abdominal was seen in one patient of group B (p= 0.470). Deterioration in blood indices was seen in 2 patients of group B while 3 patients of group A (P= 0.557). Mild ALT flare was seen in one patient of each group (p= 0.722). Conclusion: Sofosbuvir plus Velpatasvir therapy was highly efficacious and safe in non-cirrhotic and compensated cirrhotic patients with chronic viral hepatitis C. The response and tolerability of treatment was comparable in both studied groups.
Publication Details
Page(s) 313-317
Published Journal: ESCULAPIO. JOURNAL OF SERVICES INSTITUTE OF MEDICAL SCIENCES, Volume: 19, Issue: 3, Year: 2023

Request the full text from PASTIC

Keywords
Sofosbuvir, Liver Cirrhosis, hepatitis C, Sustained virological response, Velpatasvir
0

Citations

0

Downloads

38

Views